MedTrace Logo

Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents

NCT06732596 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-11-03

No results posted yet for this study

Summary

This study aims to improve retention in buprenorphine treatment, a medication used for opioid use disorder, through the use of a smartphone-delivered recovery support intervention. The intervention involves an Embodied Conversational Agent (ECA), a virtual, animated computer agent designed to simulate natural face-to-face conversations. ECAs have been shown to help individuals manage their healthcare in other settings, and this study seeks to evaluate their potential in supporting patients on medication for opioid use disorder (MOUD).

Conditions

Interventions

OTHER

Embodied conversational agent (ECA)

The app with the ECA will be provided.

OTHER

Technical support

Technical support will include assistance downloading and setting up the app on the participant's phone, walking them through a brief demonstration, and answering any questions the participant has about how to use the app.

OTHER

Additional ECA messages

Weekly text messages will be provided reminding participants to use the app on behalf of OBAT clinical staff.

OTHER

Additional incentives

Additional incentives will be provided after logging into the app for 20 days followed by monthly lotteries for those who log in 15 days per month

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Boston Medical Center

    lead OTHER

Principal Investigators

  • Karsten Lunze, MD MPH DrPH · Boston Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-30
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06732596 on ClinicalTrials.gov